(Q37965630)

26 August 2017

title

Hydroxyurea: a key player in cancer chemotherapy (English)

1 reference

26 August 2017

1 reference

1 reference

Kapish Madaan

1

1 reference

26 August 2017

Darpan Kaushik

series ordinal

2

1 reference

26 August 2017

Tarawanti Verma

series ordinal

3

1 reference

26 August 2017

publication date

1 January 2012

1 reference

Expert Review of Anticancer Therapy

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

19-29

1 reference

Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

A phase I trial of high-dose continuous-infusion hydroxyurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Chemical and functional analysis of hydroxyurea oral solutions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Hydroxyurea and hydroxamic acid derivatives as antitumor drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Sickle cell anemia--basic research reaches the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Hydroxyurea: a new antimetabolite in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Treatment of polycythemia vera with hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Synthesis and anticancer activity of novel cyclic N-hydroxyureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Hydroxyurea therapy in chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

How I treat symptomatic splenomegaly in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

EPR stopped-flow studies of the reaction of the tyrosyl radical of protein R2 from ribonucleotide reductase with hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Nitric oxide generation from hydroxyurea via copper-catalyzed peroxidation and implications for pharmacological actions of hydroxyurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Hydroxyurea fails to improve the results of MBD chemotherapy in cancer of the head and neck, but reduces toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

D-mannitol, a specific hydroxyl free radical scavenger, reduces the developmental toxicity of hydroxyurea in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

N-hydroxyurea and acyl nitroso compounds as nitroxyl (HNO) and nitric oxide (NO) donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Hydroxyurea-induced hemolytic anemia in a patient with essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Hydroxyurea induced oscillations in twelve patients with polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

Phase 1 study of high-dose hydroxyurea in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.175

21 January 2018

Identifiers

DOI

10.1586/ERA.11.175

1 reference

26 August 2017

1 reference